Active secretion and enterocytic drug metabolism barriers to drug absorption

https://doi.org/10.1016/0169-409X(95)00127-SGet rights and content

Abstract

Intestinal phase I metabolism and active extrusion of absorbed drug have only recently been recognized as major determinants of oral drug bioavailability. Both CYP3A4, the major phase I drug metabolizing enzyme in humans, and the multidrug efflux pump, P-glycoprotein (P-gp), are present at high levels in the villus enterocytes of the small intestine, the primary site of absorption for orally administered drugs. Moreover, these proteins are induced by many of the same compounds and demonstrate a broad overlap in substrate and inhibitor specificities, suggesting that they act as a concerted barrier to drug absorption. Clinical studies have demonstrated that inhibition of CYP3A4-mediated intestinal metabolism can significantly improve the oral bioavailability of a wide range of drugs. Intestinal P-gp is a major route of elimination for both orally and intravenously administered anticancer drugs in animal models, and experiements with the Caco-2 cell line have provided strong evidence that inhibition of intestinal P-gp is another means by which oral drug bioavailability could be enhanced.

References (89)

  • D.G. Bailey et al.

    Interaction of citrus juices with felodipine and nifedipine

    Lancet

    (1991)
  • G.C. Yee et al.

    Effect of grapefruit juice on blood cyclosporin concentration

    Lancet

    (1995)
  • R.L. Juliano et al.

    A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

    Biochim. Biophys. Acta

    (1976)
  • A.M. Schinkel et al.

    Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

    Cell

    (1994)
  • K. Ueda et al.

    Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone

    J. Biol. Chem.

    (1992)
  • P.S. Burton et al.

    Evidence for a polarized efflux for peptides in the apical membrane of Caco-2 cells

    Biochem. Biophys. Res. Commun.

    (1993)
  • J. Hunter et al.

    Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells

    J. Biol. Chem.

    (1993)
  • P.F. Augustijns et al.

    Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporine A transport

    Biochem. Biophys. Res. Commun.

    (1993)
  • Y.K. Tam

    Individual variation in first-pass metabolism

    Clin. Pharmacokinet.

    (1993)
  • D.R. Krishna et al.

    Extrahepatic metabolism of drugs in humans

    Clin. Pharmacokinet.

    (1994)
  • D.J. Back et al.

    First-pass metabolism by gastrointestinal mucosa

    Aliment. Pharmacol. Ther.

    (1987)
  • P.H. de Waziers et al.

    Cytochrome P450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues

    J. Pharmacol. Exp. Ther.

    (1990)
  • V.J. Wacher et al.

    Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy

    Mol. Carcinog.

    (1995)
  • P.B. Watkins

    Non-invasive tests of CYP3A enzymes

    Pharmacogenetics

    (1994)
  • P.B. Watkins et al.

    Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man

    J. Clin. Invest.

    (1987)
  • G.I. Murray et al.

    The immuno-cytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450

    Br. J. Pharmacol.

    (1988)
  • J.C. Kolars et al.

    Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes

    J. Clin. Invest.

    (1992)
  • J.C. Kolars et al.

    CYP3A gene expression in human gut epithelium

    Pharmacogenetics

    (1994)
  • R.A. McKinnon et al.

    Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues

    Gut

    (1995)
  • T. Shimada et al.

    Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 caucasians

    J. Pharmacol. Exp. Ther.

    (1994)
  • R.P. Forsyth et al.

    Normal distribution of cardiac output in the unanesthetized, restrained rhesus monkey

    J. Appl. Physiol.

    (1968)
  • D. Levêque et al.

    P-glycoprotein and pharmacokinetics

    Anticancer Res.

    (1995)
  • F. Thiebaut et al.

    Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

  • J. Buchthal et al.

    Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa

    Eur. J. Clin. Pharmacol.

    (1995)
  • K.S. Lown et al.

    Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test

    Drug Metab. Dispos.

    (1994)
  • S.A. Wrighton et al.

    Identification of a polymorphically expressed member of the human cytochrome P-450III family

    Mol. Pharmacol.

    (1989)
  • S.A. Wrighton et al.

    Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3)

    Mol. Pharmacol.

    (1990)
  • E.G. Schuetz et al.

    Regulation of human liver cytochromes P-450 in family 3A in primary and continuous culture of human hepatocytes

    Hepatology

    (1993)
  • J.C. Gorski et al.

    Regioselective biotransformation of midazolam by members of the cytochrome P450 3A (CYP3A) subfamily

    Biochem. Pharmacol.

    (1994)
  • K.E. Thummel et al.

    Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients

    J. Pharmacol. Exp. Ther.

    (1994)
  • K.E. Thummel et al.

    Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter-and intraindividual hepatic CYP3A variability after liver transplantation

    J. Pharmacol. Exp. Ther.

    (1994)
  • P.B. Watkins et al.

    Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450

    J. Clin. Invest.

    (1989)
  • P.E. Warner et al.

    Sumatriptan absorption from different regions of the human gastrointestinal tract

    Pharm. Res.

    (1995)
  • L.F. Lacey et al.

    Single dose pharmacokinetics of sumatriptan in healthy volunteers

    Eur. J. Clin. Pharmacol.

    (1995)

    • Cited by (110)

    • Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review

      2023, Saudi Pharmaceutical Journal

    • A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: A cross-sectional survey with 500 bioequivalence studies

      2013, Journal of Pharmaceutical Sciences
      Citation Excerpt :

      Considering that the diagnostic indicators in this survey were calculated using only a single in vitro result from a dissolution test performed under pharmacopeial or manufacturer-validated conditions to assess quality control, it seems safe to expect a higher accuracy of the diagnostic test when performing the complete set of in vitro dissolution profiles required to support a biowaiver request. The absorption of a class 3 drug is more complex than that of a class 1 drug because its absorption is segmentally dependent along the small intestine,53–57 and it is also mediated by uptake transporters.27,58 Therefore, the absorption of a class 3 drug could be more affected by certain excipients, which interact with gastrointestinal motility, reducing the intestinal transit time,59 and/or interact with uptake transporters.58

    • Loss of orally administered drugs in GI tract

      2012, Saudi Pharmaceutical Journal
      Citation Excerpt :

      Also the attempts to define drug metabolism processes have been limited largely to various metabolic isoenzymes of the liver. Benet et al. (1996) and Wacher et al. (1996), were the first to hypothesize that for many drugs poor bioavailability could be due to the action of intestinal enzymes. They had performed certain cellular, animal and human studies and arrived at a conclusion that intestinal metabolic enzymes and efflux transporters working coordinately as a protective mechanism could be the cause for the poor bioavailability of certain drugs.

    • Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug

      2009, Journal of Controlled Release

    • Intranasal delivery: Physicochemical and therapeutic aspects

      2007, International Journal of Pharmaceutics

    • Lipid-Based Oral Formulation Strategies for Lipophilic Drugs

      2018, AAPS PharmSciTech
    View all citing articles on Scopus
    View full text
    Copyright © 1996 Published by Elsevier B.V.